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Background: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors
although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose
the characterization and treatment outcomes of pancreatic metastases from RCC.
Methods: Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20
(7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively
reviewed and statistically analyzed.
Results: The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile
range: IQR, 7.8–15.5 years) and 3.8 years (IQR, 2.1–5.5 years), respectively. Median duration from diagnosis of RCC to
pancreatic metastasis was 7.8 years (IQR, 4.2–12.7 years). During this observation period, the estimated median overall
survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The
probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively.
The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was
significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical
management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for
these surgeries was 3.5 years (IQR, 1.9–5.2 years), the estimated median recurrence-free survival was 1.8 years. For the
patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the
median follow-up period was 4.1 years (IQR, 3.0–4.4 years), no disease progression was observed.
Conclusions: The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after
nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good
outcomes.
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Among pancreatic malignant tumors, metastatic pancreatic
tumors are rare with the estimated frequency ranging from
2% to 5% [1-3]. Pancreas metastases from renal cell cancer
(RCC) are also rare, with less than 2% reported in autopsy
series [4,5]. In clinical practice, however, RCC is one of the
most frequent primary sites for metastatic pancreatic tumors
[6-8]. In addition, metastases to the pancreas from other or-
gans are typically associated with disseminated systemic* Correspondence: takeshi.yuasa@jfcr.or.jp
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unless otherwise stated.disease, but in the case of RCC, the pancreas is the only
metastatic site in about half of cases and is referred to as
isolated pancreatic metastasis [1-3,6-8]. Therefore, it is im-
portant to discuss the treatment strategy of pancreatic me-
tastasis derived from RCC. Isolated pancreatic metastases
from RCC are usually asymptomatic and are often detected
during follow-up investigations after surgery for a primary
lesion or as an incidental finding on imaging studies done
for an unrelated indication [1-3,6-8]. Pancreatic metastasect-
omy of RCC was reported to improve survival in selected
patients [6-8].
In a retrospective study, we reported that RCC was the
most frequent primary site in patients with pancreatichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients with pancreatic metastases from RCC, surgical re-
section is the treatment of choice for long-term survival
(median overall survival [OS] period 45 months) [8].
However, the opportunity for surgical exploration is lim-
ited. Patients with multiple metastatic sites and wide-
spread systemic disease at the time of diagnosis are not
good candidates for resection. These patients usually
undergo immunotherapy as well as molecular targeted
therapy, which were introduced into the clinical practice
for the treatment of metastatic RCC [9,10]. In this study,
we retrospectively investigated the characterization and




The medical records of patients with pancreatic metastases
secondary to RCC, who were treated in the Cancer Institute
Hospital (Japanese Foundation for Cancer Research, Tokyo,
Japan) between 1999 and 2013, were retrospectively
reviewed. In all patients, pancreatic metastasis was con-
firmed by computed tomography and/or magnetic reson-
ance imaging. We considered clinical and geometric factors
including age, gender, Eastern Cooperative Oncology Group
performance status, presence or absence of extra-pancreatic
metastases, solitary or multiple pancreatic metastases, the
interval from diagnosis of RCC to initial systemic therapy,
surgical treatment, and systemic medical treatment, includ-
ing cytokine therapy and targeted agents (sorafenib, suniti-
nib, axitinib, and everolimus). In this study, we applied the
International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) model, which stratifies patients into
three risk groups (favorable: no risk factors, intermediate:
one or two risk factors, and poor: three, four, five, or six risk
factors) [11]. Histopathology was reviewed according to the
2004 World Health Organization classification [12]. This
study was carried out in compliance with the Helsinki dec-
laration and was approved by the institutional review board
at Cancer Institute Hospital.
Statistical analysis
Survival time was defined as the time from diagnosis of pan-
creatic metastasis to death or the last follow-up date. OS
was estimated using the Kaplan–Meier method. The rela-
tionship between survival period and each of the variables
was analyzed using the log-rank test for categorical variables.
Regarding the comparison of characteristics between pa-
tients with pancreatic and non-pancreatic metastases from
RCC, we used chi-square test or Student’s t-test for categor-
ical variables. Statistical analyses were performed using the
Statistical Package for Social Sciences, version 17.0 for Win-
dows (SPSS Inc., Chicago, IL). Two-tailed P < 0.05 was con-
sidered significant.Results
Characteristics of patients and their pancreatic
metastases
Of 262 RCC patients with metastases, 20 (12.0%) were diag-
nosed with pancreatic metastases. The median follow-up
period from the diagnosis of RCC and pancreatic metastases
was 13.4 years (inter-quartile range: IQR, 7.8–15.5 years)
and 3.8 years (IQR, 2.1–5.5 years), respectively. Patient char-
acteristics and demographic data are shown in Table 1. All
20 patients had undergone nephrectomy and all patients
were clear cell subtype. Synchronous pancreatic metastasis
was found in three patients at the time of RCC diagnosis
and pancreatic metastasis was discovered in the remaining
17 patients during follow-up investigations after surgery. In
patients with metachronous pancreatic metastasis, the me-
dian duration from diagnosis of RCC to pancreatic metasta-
sis was 7.8 years (IQR, 4.2–12.7 years). During this relatively
long observation period, three patients (15%) died from
RCC and the estimated median OS time from the diagnosis
of RCC to death or from pancreatic metastases to death was
not reached (Figure 1A,B). The probability of patients sur-
viving after pancreatic metastases at 1, 3, and 5 years was
100, 87.7, and 78.9%, respectively (Figure 1A). Among these
patients, 9 of 20 (45%) had extra-pancreatic metastases at
the time of diagnosis of pancreatic metastasis (Table 1). Sur-
gical management for pancreatic metastasis was performed
in 15 patients (75%). Among these patients, two patients
underwent pancreas metastasectomy twice and one patient
three times. One patient underwent total pancreatectomy as
the second surgical procedure, whereas two patients under-
went partial pancreatectomy, both as second and third sur-
gical procedures. The latter two patients, who underwent
surgery for pancreas preservation, are alive and show no
signs of glucose metabolic disorder. Two patients, who had
extra-pancreatic and lung metastases simultaneously, under-
went surgical treatment for pancreas metastases as a pallia-
tive treatment. In the remaining 13 patients, 17 pancreas
metastasectomies were performed as a radical treatment.
Regarding the surgical procedure for pancreatic metastasis,
two, six, two, six, and one patients underwent enucreation,
pancreatoduodenectomy, segmental pancreatectomy, distal
pancreatectomy, and total pancreatectomy, respectively.
Average number and size of these resected pancreatic tu-
mors was 1.8 (range, 1–6) and 20.9 mm (range, 5–53 mm),
respectively. The median follow-up period for these surger-
ies was 3.5 years (IQR, 1.9–5.2 years) and the estimated me-
dian recurrence-free survival was 1.8 years (95% confidence
interval [CI], not calculated) (Figure 1C). The probability of
recurrence-free patients after metastasectomy at 1 and
5 years was 78.6% and 46.3%, respectively (Figure 1C). The
30-day perioperative morbidity rate, which included pleural
effusion and wound infection, was 16%. There was no peri-
operative mortality. Molecularly targeted therapies were
given to six (30%) patients with metastatic disease. Of these
Table 1 Comparison of characteristics between pancreatic and non-pancreatic metastasis from RCC (n = 262)
Variables Pancreatic metastasis Non-pancreatic metastasis P
Male/female n (%) 12/8 (60%/40%) 184/58 (76%/24%) 0.11
Age at Dx of RCC* 59.7 (52.5–62.5) 61.7 (54.6-69.3) 0.16
Age at Dx of metastasis 66.2 (62.3–69.9) 63.6 (56.4-70.2) 0.09
Metastatic sites n (%)
Pancreas 20 (100%) 0 (0%)
Lung 4 (20%) 194 (80%) <0.0001
Bone 0 (0%) 63 (26%) 0.009
Kidney 5 (25%) 2 (1%) <0.0001
Lymph nodes 3 (15%) 77 (32%) 0.117
Liver 3 (15%) 19 (8%) 0.268
Adrenal gland 2 (10%) 39 (16%) 0.469
Synchronous: metachronous (n) 3 /17 (15%/85%) 153/89 (63%/37%) <0.0001
Period from Dx of RCC to metastasis (years)* 7.8 (4.2–12.7) 0 (0–0.7) <0.0001
Metastasectomy (n) (Yes/No) 15/5 (75%/25%) 56/186 (23%/77%) <0.0001
Molecular targeted therapy (n) (Yes/No) 6/14 (30%/70%) 98/144 (40%/60%) 0.357
Median OS from the Dx of metastasis (years)# Not reached 2.7 (1.8-3.6) <0.0001
*Numbers represent Median (IQR), #Numbers represent Median (95% CI), Dx, diagnosis; IQR, inter-quartile range; RCC, renal cell cancer; OS, overall survival;
95% CI, 95% confidence interval.
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targeted therapies. Regarding the patients who had under-
went surgical resection, one patient began to receive tar-
geted therapy due to pancreatic and lung metastases. Both
sorafenib and sunitinib, sorafenib alone, and sunitinib alone
were administered to one, one, and four patients, respect-
ively. Remarkable regression was observed in all six patients
(one complete responder and five partial responders). In
addition, when the median follow-up period was 4.1 years
(IQR, 3.0–4.4 years), no disease progression was observed in
any of the six patients.
Comparison of characteristics between pancreatic and
non-pancreatic metastasis from RCC
In order to identify the characteristics of pancreatic me-
tastasis from RCC, we compared the clinical variables be-
tween pancreatic and non-pancreatic metastasis from
RCC (n = 262). The median follow-up period from the
diagnosis of RCC and metastases of the patients with non
pancreas metastasis was 2.0 years (IQR, 0.6–5.8 years) and
1.4 (IQR, 0.6–3.9 years), respectively. We summarized the
characteristics of these patients and the results are shown
in Table 1. The distribution of metastatic organ is appar-
ently different between these two groups. The patients
with pancreatic metastasis had less frequencies of lung
and bone metastasis and more frequencies of contra-
lateral kidney metastasis (Table 1). The estimated OS time
from the diagnosis of metastases to death of the patients
with pancreatic (median OS: not reached) was signifi-
cantly longer than that of the patients with non-pancreaticmetastasis (median OS: 2.7 years, 95% CI: 1.8–3.6 years)
(P < 0.0001).
Risk factors for poor outcome of the patients with
pancreatic metastasis in univariate analysis
Although we searched for risk factors of poor outcome
using univariate analysis, we could not find any. How-
ever, when we applied the IMDC model, which stratifies
patients into three risk groups (favorable: n = 16, inter-
mediate: n = 4, and poor: n = 0), the estimated median
OS time from the diagnosis of pancreatic metastasis was
not reached for populations classified as favorable and
was 2.5 years for populations classified as intermediate,
which resulted in distinct separation of the OS curves
(P = 0.013) (Figure 2A).
Next, to investigate the contribution of surgery to the
outcome, we separated patients into two groups, i.e., those
who received surgical treatment and those who did not.
Both of median OS periods of these two groups did not
reach significance (Figure 2B). In this study, the contribu-
tion of surgery to the outcome of patients with pancreatic
metastases from RCC was difficult to assess.
Pathologic findings
When we examined the pathological findings of the pan-
creatic metastases, which were resected by pancreatic
metastasectomy, we observed a distinctive feature of
RCC-derived metastatic pancreatic tumors, a fibrous
pseudocapsule (Figure 3A–D). This feature is not nor-
mally observed in metastases from other organs. There
Figure 1 Overall survival curves and recurrence-free survival curve
of patients with pancreas metastasis from renal cell cancer. Overall
survival curve from the diagnosis of renal cell cancer (A) (n= 20). Overall
survival curve from the diagnosis of pancreatic metastasis (B) (n= 20).
Recurrence-free survival curve from radical surgical management of
pancreatic metastases (C) (n= 17).
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derived metastatic regions and those from other organs.
Discussion
Our study demonstrated that patients with pancreatic me-
tastases from RCC have relatively longer survival times
than patients with metastatic RCC. Recent reviews show
that the 5-year OS rate in patients who have received sur-
gical treatment for pancreatic RCC metastases was 66–
78% [7,13]. The reason why better outcomes are achievedin patients with pancreatic RCC metastases than in pa-
tients with metastasis to other sites is unknown. From our
study and those of others, we suggest that the following
factors may explain why patients with pancreatic RCC me-
tastases had better OS: (a) late recurrence, which is a good
prognostic factor in the IMDC score; (b) few of the pa-
tients were categorized with a poor prognosis using the
IMDC score; (c) efficient surgical and medical treatments;
(d) high population of isolated RCC metastatic disease to
the pancreas; and (e) presence of a pseudocapsule in the
pathological analysis (Figure 3A–D).
In the cytokine era, prognostic factors that predict the
outcome in patients with metastatic RCC were defined
by Motzer et al. at Memorial Sloan Kettering Cancer
Center (MSKCC), which resulted in the development of
an MSKCC score [14]. In the era of molecular targeted
therapy, several studies have investigated clinical prog-
nostic factors [14-17]. Among these, the score developed
by Heng et al. (IMDC score) is the most popular and is
widely used in clinical practice [11]. Both studies dem-
onstrated that a poor prognostic factor was a time of less
than one year from diagnosis to treatment. In addition,
we recently reported that these prognostic scores were
associated with prognosis among Japanese patients with
metastatic RCC [18,19]. Very recently, the IMDC study
also demonstrated that late relapses had significantly
longer progression-free survival (P = 0.005) and OS (P =
0.004) [20]. These studies and the current study suggest
that late recurrence, which is also one of the characteris-
tics of pancreas metastasis from RCC, is an important
factor for long- term survival.
When the median follow-up period for the patients
treated with the targeted agents was 4.1 years, no pro-
gression was observed in all six patients. However, pa-
tient number was small, so the absence of disease
progression should be confirmed in future large scale
studies. As the efficacy of the targeted agent was excel-
lent in our study, the contribution of surgery to the out-
come of patients with pancreatic metastases from RCC
was difficult to assess (Figure 2B). In a recent review, the
estimated median OS period and 5-years OS rate of 112
patients with pancreatic metastases from RCC after sur-
gical treatment was 8.75 years (range 0.6 months to
18.5 years) and 66%, respectively [12]. Similarly, in a re-
cent single-center retrospective study, the survival of 23
patients undergoing surgery was compared to that of 13
non-surgically treated patients. The actual 5-year OS
rates and median disease-free survival were 88% and
44 months in the surgical group and 47% and 27 months
in the non-surgical group, respectively (P = 0.02) [7]. In
our study, 2-and 5-year OS rates of the surgically treated
patients were 80% and 72%, respectively. In addition, 1-
and 5-year recurrence-free survival rates after metasta-
sectomy were 78.6% and 46.3%, respectively (Figure 1C).
Figure 2 Overall survival curves of patients with pancreatic metastasis from the diagnosis of pancreatic metastasis stratified by the
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk scores (A), by surgical or medical treatment (B).
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who were not administered targeted agents was 1.8 years,
which was better than the progression-free survival time
of patients who were not administered targeted agents
[9,10,21], although seven of 17 cases recurred after sur-
gical treatment. Although we consider that surgical re-
section should not be the only therapeutic tool against
pancreatic metastases from RCC, surgery is still an im-
portant treatment modality even in this era of targeted
therapy. We believe that a combination of various treat-
ment approaches during the different stages of meta-
static RCC could result in synergistic antitumor activity.
A high proportion of patients did not have metastases
other than those to the pancreas; this is referred to as iso-
lated pancreatic metastasis. In our study, 45% of patients did
not have other metastatic lesions, which is similar to the
findings of other studies [1-3,6,7]. As there was no difference
between the survival period with or without other metasta-
ses, the contribution of these metastases to the outcomes of
the patients is difficult to assess. A relatively improvedFigure 3 Histopathological findings of pancreatic metastases
from renal cell cancer (A–D). High magnification images of the
cells (B and D) captured in the red squares seen on A and C,
respectively.outcome may reflect a special non-aggressive characteristic
of pancreatic metastasis from RCC. In addition, we cannot
predict the spontaneous regression, especially in asymptom-
atic patients with a long disease free interval (>5 years).
These patients might possibly survive anyway without sur-
gery and/or targeted agents.
We investigated the histological features of RCC pancre-
atic metastasis, as tumor non-aggressiveness could be a
pathological feature. In the current study, a pseudocapsule,
which consists of fibrous tissue between the tumor and the
pancreatic parenchyma, was observed in all of the surgically
resected RCC pancreatic metastases. Some studies of liver
metastasis have indicated that a pseudocapsule is a favorable
prognosis factor after resection [22-25]. Okano et al. and
Iguchi et al. demonstrated that a pseudocapsule has a
beneficial effect on patients and increases recurrence-free
survival of patients with colorectal cancer after hepatic re-
section [22,23]. Okano et al. and Garancini et al. demon-
strated that a pseudocapsule around liver metastases from
gastric cancer is a favorable prognostic factor and is closely
associated with patient survival [24,25]. They speculated that
the formation of a pseudocapsule could constitute a protect-
ive immunoinflammatory reaction against the metastatic
nodule, and that the host defense reaction created a wall to
inhibit cancer cell diffusion. Therefore, pseudocapsules may
be considered as beneficial in patients with pancreatic me-
tastases from RCC.
Conclusion
We retrospectively investigated the clinical outcome of pa-
tients with pancreatic metastases from RCC and deter-
mined the characteristics of these metastases. The pancreas
was frequently the only metastatic site and metastasis typic-
ally occurred a long time after nephrectomy. The OS period
of these patients is long and both surgical and medical
treatment demonstrated good efficacy. The decision mak-
ing as well as surgical indication for patients with the meta-
static lesion is always difficult issue. Currently we are giving
all the information demonstrated here and asking the pa-
tient’s preference “surgery” or “targeted therapy”.
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